NEW YORK (GenomeWeb News) – Aureon Laboratories will work with MD Anderson Cancer Center to search for biomarkers associated with non-small cell lung cancer patients, the Yonkers, NY-based company said on Monday.
Under the collaboration, Aureon will work with MD Anderson associate professor of pathology Ignacio Wistuba to quantitate and evaluate biomarkers that may be linked to disease progression and the probability of survival. The project will use Aureon’s systems pathology platform, which uses morphometric imaging on formalin-fixed, paraffin-embedded tissue specimens, to study tissue from around 350 NSCLC patients.
The company said its system allows it to quantitate and integrate histological attributes and multiplexed protein biomarkers on a cell-by-cell basis. Aureon also said it has developed a multivariate algorithm that can integrate histological, molecular, and clinical features in order to identify phenotypes associated with the course of a disease.
This approach “allows a better understanding of the biological context in terms of assessing therapeutic response,” Aureon President and CEO Vijay Aggarwal said in a statement.
Aggarwal also said that the company’s system has shown utility in stratifying NSCLC patients who are treated with Iressa, a common drug treatment for the disease.